La vendita allo scoperto per Bruker dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Bruker. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Bruker (NASDAQ:BRKR) Azioni, Report sulle vendite allo scoperto

Bruker

Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific.

Bruker Corp

General

BRKR

Bruker shares are trading lower after the company lowered its FY24 adjusted EPS and revenue guidance.

<p><strong>Fiscal Year 2024 (FY 2024) Financial Outlook</strong></p>
<p>For FY 2024, Bruker now expects revenues of $3.34 to $3.37 billion, compared to FY 2023 revenues of $2.96 billion, with 12.5% to 13.5% year-over-year reported revenue growth, including:</p>
<ul>
<li>Organic revenue growth of 3% to 4%,</li>
<li>Contribution from M&amp;A of approximately 9.5%,</li>
<li>Foreign currency translation impact approximately neutral,</li>
<li>CER revenue growth of approximately 13%.</li>
</ul>
<p>Bruker now expects FY 2024 non-GAAP EPS of $2.36 to $2.41, compared to FY 2023 non-GAAP EPS of $2.58.</p>


News

Guidance

Bruker Sees FY24 Adj. EPS $2.36-$2.41 (Prior $2.59-$2.64) vs $2.59 Est., Revenues $3.34B-$3.37B (Prior $3.38B-$3.44B) vs $3.40B Est.

Earnings

Earnings Beats

Bruker Q3 2024 Adj. EPS $0.60 Beats $0.59 Estimate, Sales $864.400M Beat $859.384M Estimate

<p>Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) will release its quarterly earnings report on Tuesday, 2024-11-05. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Bruker to report an <strong>earnings per share</strong> (EPS) of $0.61.</p>
<p>Investors in Bruker are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Overview of Past Earnings</h3>
<p>In the previous earnings release, the company missed EPS by $0.02, leading to a 2.99% drop in the share price the following trading session.</p>
<p>Here's a look at Bruker's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.54</td>
<td>0.46</td>
<td>0.68</td>
<td>0.63</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.52</td>
<td>0.53</td>
<td>0.70</td>
<td>0.74</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-3.0%</td>
<td>-0.0%</td>
<td>4.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730736246_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Bruker were trading at $59.29 as of November 01. Over the last 52-week period, shares are up 1.68%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Insights on Bruker</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Bruker.</p>
<p>Analysts have provided Bruker with 3 ratings, resulting in a consensus rating of Outperform. The average one-year price target stands at $75.0, suggesting a potential 26.5% upside.</p>
<h3>Peer Ratings Overview</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of Charles River, Medpace Hldgs and Repligen, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>Charles River received a Neutral consensus from analysts, with an average 1-year price target of $200.92, implying a potential 238.88% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Medpace Hldgs, with an average 1-year price target of $375.71, suggesting a potential 533.68% upside.</li>
<li>The consensus outlook from analysts is an Outperform trajectory for Repligen, with an average 1-year price target of $192.5, indicating a potential 224.68% upside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
<p>The peer analysis summary outlines pivotal metrics for Charles River, Medpace Hldgs and Repligen, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bruker</td>
<td>Outperform</td>
<td>17.42%</td>
<td>$384.60M</td>
<td>0.47%</td>
</tr>
<tr>
<td>Charles River</td>
<td>Neutral</td>
<td>-3.19%</td>
<td>$353.71M</td>
<td>2.44%</td>
</tr>
<tr>
<td>Medpace Hldgs</td>
<td>Neutral</td>
<td>8.29%</td>
<td>$169.01M</td>
<td>11.72%</td>
</tr>
<tr>
<td>Repligen</td>
<td>Outperform</td>
<td>-3.20%</td>
<td>$76.76M</td>
<td>0.17%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Bruker ranks at the top for Revenue Growth and Gross Profit among its peers. It is in the middle for Return on Equity.</p>
<h3>Discovering Bruker: A Closer Look</h3>
<p>Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific.</p>
<h3>Financial Milestones: Bruker's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Bruker's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>17.42%</strong> as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Bruker's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>0.95%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Bruker's ROE excels beyond industry benchmarks, reaching <strong>0.47%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Bruker's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.15%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Bruker's debt-to-equity ratio surpasses industry norms, standing at <strong>1.27</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<p><a href="https://www.benzinga.com/quote/BRKR/earnings"><strong>To track all earnings releases for Bruker visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Look Ahead: Bruker's Earnings Forecast

<p><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bruker.com&amp;esheet=54137544&amp;newsitemid=20241017641053&amp;lan=en-US&amp;anchor=Bruker+Corporation&amp;index=1&amp;md5=530321542f67933615f7393d4ba8458f">Bruker Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) today announced that the European Unified Patent Court (UPC) has ruled in favor of its NanoString business, invalidating European Patent No. 2794928B1 (the "928 Patent"), which has been asserted by 10x Genomics against NanoString's CosMx&#xAE; Spatial Molecular Imager (SMI) products in Europe. Today's ruling follows the May 2024 decision of the German Federal Patent Court, which declared the 928 Patent invalid and revoked the patent in Germany. An appeal is pending in that case. Today's decision of the UPC expands on that German invalidity ruling to further invalidate the 928 Patent in France and The Netherlands. The ruling of the UPC is subject to appeal.</p>


Legal

NSTGQ

European Unified Patent Court Rules In Favor Of Bruker And NanoString, Invalidating Patent Asserted By 10x Genomics Against NanoString's CosMx SMI Products

<p>Barclays  analyst Terence Malone   initiates coverage on Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Overweight rating and announces Price Target of $75.</p>


Price Target

Initiation

Analyst Ratings

Barclays Initiates Coverage On Bruker with Overweight Rating, Announces Price Target of $75

Health Care

Bruker Announced The Formation Of A New Division, Bruker Spatial Biology Bringing Together In The Two Businesses Of NanoString Technologies And Canopy Biosciences, Along With Its Subsidiary Bruker Spatial Genomics (Formerly Acuity Spatial Genomics)

<p><strong>Bruker Corporation&nbsp;</strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brkr#NASDAQ">BRKR</a>) recently announced the acquisition of Dynamic Biosensors GmbH, or DBS, a pioneering company known for its development in biosensors. The acquisition is aimed at boosting Bruker&#39;s biophysical portfolio, which is used for analyzing molecular interactions and kinetics. Financial details of the transaction were not disclosed.</p>
<p>Hence, the latest strategic acquisition is expected to strengthen Bruker&#39;s position in the pharma and biotech industries. The acquisition will leverage Bruker&#39;s leading high-throughput Surface Plasmon Resonance (&quot;SPR&quot;) portfolio and Dynamic Biosensors&#39; unique instruments.</p>
<h2>BRKR&#39;s Likely Stock Trend Following the News</h2>
<p>Subsequent to the news, the share price of BRKR moved north 1% to $67.46 on Wednesday. The company is gaining a high level of synergies from its continuous effort to reinforce its leading position within the pharma and biotech industries. Given the latest acquisition announcement, we expect market sentiment toward BRKR stock to continue to remain positive.</p>
<p>BRKR currently has a market capitalization of $9.97 billion. The company has a trailing four-quarter average earnings surprise of 10.09%.</p>
<h2>Significance of Bruker&#39;s Latest Acquisition</h2>
<p>DBS develops and markets innovative technologies for studying complex molecular interactions and kinetics to support drug discovery in the pharma and biotech industries, as well as in basic and medical research. The new Dynamic Biosensor heliX&nbsp;instrument performs single-cell Interaction Cytometry (scIC) for kinetic measurements directly on cells, retaining the molecules&#39; native membrane environment. Bruker&#39;s SPR portfolio includes all new SPR #64 &lsquo;Triceratops&#39;, and the 24 and 32-spot Sierra-Pro SPR systems.</p>
<p>The Bruker SPR portfolio is a great match for DBS&#39;s products. Hence, following the acquisition, the combined Bruker Biosensors business will offer one of the most innovative ranges of instruments, workflows, and consumables for studying intermolecular and molecule-cell interactions in the drug discovery pipeline. The acquisition should help Bruker establish itself as a new technology leader in biosensors with a differentiated offering.</p>
<p>In fiscal 2025, Bruker expects its Biosensors business to have an additional revenue gain of more than $5 million from the DBS acquisition, with no material EPS impact.</p>
<h2>Other Recent Developments by Bruker</h2>
<p>In August, Bruker completed the installation and acceptance of a 1.2 GHz Avance NMR spectrometer at the Korea Basic Science Institute (&quot;KBSI&quot;). As the first 1.2 GHz NMR system in the Asia-Pacific region, it sets a new benchmark for molecular, cell biology and disease research using ultra-high-field NMR.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/a8/80555.jpg?v=1793157732" /></p>
<p>Image Source: Zacks Investment Research</p>
<p>The same month, the company announced a strategic investment in&nbsp;NovAliX &mdash; a preclinical Contract Research Organization specializing in expert drug discovery services. Bruker&#39;s partnership with NovAliX should enable both companies to accelerate the development, incubation, deployment and support of advanced biophysical methods. The collaboration will leverage Bruker&#39;s leading post-genomic solutions competencies, combined with NovAliX&#39;s expert services and innovation.</p>
<h2>Industry Prospects Favor Bruker</h2>
<p>Per a Grand View Research report, the global biosensors market was valued at $28.9 billion in 2023 and is expected to witness a compound annual growth rate of 8.0% from 2024 to 2030. The demand for biosensors is increasing due to the diversity of medical applications, the increasing number of diabetic patients, the high demand for compact diagnostic devices and rapid technological improvement.</p>
<h2>BRKR&#39;s Price Performance</h2>
<p>In the past year, BRKR&#39;s shares have risen 6% compared with the industry&#39;s 23.8% growth.&nbsp;</p>
<h2>BRKR&#39;s Zacks Rank and Key Picks</h2>
<p>BRKR currently carries a Zacks Rank #3 (Hold).</p>
<p>Some better-ranked stocks in the broader medical space are <strong>TransMedics Group</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>), <strong>AxoGen</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axgn#NASDAQ">AXGN</a>) and <strong>OrthoPediatrics</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kids#NASDAQ">KIDS</a>). While TransMedics sports a Zacks Rank #1 (Strong Buy) at present, AxoGen and OrthoPediatrics carry a Zacks Rank #2 (Buy) each.</p>
<p>Estimates for TransMedics&#39; 2024 earnings per share have moved up 0.8% to $1.22 in the past 30 days. Shares of the company have soared 189.3% in the past year compared with the industry&#39;s 20.7% growth. TMDX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.</p>
<p>Estimates for AxoGen&#39;s 2024 loss per share have remained constant at 1 cent in the past 30 days. Shares of the company have surged 212.1% in the past year compared with the industry&#39;s 20.7% growth. AXGN&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.5%. In the last reported quarter, it delivered an earnings surprise of 200%.</p>
<p>Estimates for OrthoPediatrics&#39; 2024 loss per share have declined to 92 cents from 96 cents in the past 30 days. In the past year, shares of KIDS have lost 5.8% against the industry&#39;s 20.7% growth. In the last reported quarter, it delivered an earnings surprise of 25.81%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 26.81%.</p>
<p><a href="https://www.zacks.com/stock/news/2347087/bruker-stock-gains-from-its-latest-acquisition-of-dynamic-biosensors?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2347087">To read this article on Zacks.com click here.</a></p>


Large Cap

Mid Cap

Offerings

Small Cap

Events

Markets

Trading Ideas

AXGN

KIDS

TMDX

Bruker Stock Gains From Its Latest Acquisition of Dynamic Biosensors

<p>October 7th, 2024: Bruker BioSpin Group today announced the acquisition of the Electron Paramagnetic Resonance (EPR) business of Bridge12, a Massachusetts-based company (<a href="http://www.bridge12.com/">www.bridge12.com</a>). With Bridge12's solutions for certain cutting-edge research using EPR technology, Bruker further enhances its suite of EPR spectroscopy offerings.</p>
<p>Bridge12 offers modular EPR bridges for pulsed spectroscopy, high-field EPR spectrometers for multi-frequency experiments, microwave amplifiers, and EPR probes. Their innovative technology and collaborative research initiatives aim to advance EPR spectroscopy, providing superior versatility in EPR instrumentation.</p>


Bruker Strengthens EPR Offerings, Acquires Bridge12's Advanced Spectroscopy Technology, Financial Terms Undisclosed

<p><strong>Bruker Corporation</strong>&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brkr#NASDAQ">BRKR</a>) growth is backed by strong sales within its X-Ray and Nano Analytics businesses. Within the PCI division, expanding customer demand for pre-clinical MRI systems is highly encouraging. Meanwhile, the impact of macroeconomic pressure and currency fluctuation is likely to hurt the company&#39;s operational results.</p>
<p>In the past year, this Zacks Rank #3 (Hold) company&#39;s shares have gained 10.4% compared with the industry&#39;s 27.5% growth and the S&amp;P 500 composite&#39;s 34.9% gain.</p>
<p>This renowned medical device company has a market capitalization of $11.77 billion. It has a 2025 earnings growth rate of 17.6%, which is much higher than the industry&#39;s 13.8% growth rate. BRKR&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.1%.</p>
<p>Let&#39;s delve deeper.</p>
<h2>Bruker&#39;s Key Upsides</h2>
<p><strong>Bright Prospects Within Nano Business Segment:</strong>&nbsp;The segment caters to a large set of customers, such as academic institutions, governmental customers, nanotechnology companies, semiconductor companies, raw material manufacturers, industrial companies, biotechnology and pharmaceutical companies and other businesses that are involved in materials research and life science research analysis. The business is seeing robust revenue growth across its end markets, including academic, government, industrial and semiconductor metrology.&nbsp;</p>
<p>During the first half of 2024, the company&#39;s advanced X-Ray and Nano Analytics businesses delivered strong sales, backed by Nano&#39;s robust revenue growth. Nano&#39;s strong growth is driven by the rising demand in academic and government markets. The Nanostring acquisition is expected to be both strategically and financially beneficial, promising a high return on investment for Bruker.</p>
<p><strong>The Potential of Preclinical Imaging (PCI) Market: </strong>Per Grand View Research, the global PCI market was valued at $4.30 billion in 2023 and is likely to witness a CAGR of 4.6% up to 2030. Therefore, this translates into a golden opportunity for Bruker to expand its foothold in the PCI market and earn higher profits from this division.</p>
<p>Bruker offers advanced PCI solutions for a broad spectrum of application fields. Moreover, this division is experiencing increasing customer demand for higher-strength pre-clinical magnetic resonance imaging systems. Earlier this year, Bruker filled a critical gap in its PCI portfolio with the acquisition of Spectral Instruments Imaging LLC, a leader in preclinical in-vivo optical imaging systems.</p>
<h2>Bruker&#39;s Key Downsides</h2>
<p><strong>Unfavorable Currency Movement</strong>: Bruker generates a substantial portion of its revenues in the international markets, primarily in Germany and other countries in the European Union, Switzerland and Japan.&nbsp; As a result, currency fluctuations continue to result in foreign currency transaction losses for the company. In addition, currency fluctuations are likely to cause the price of Bruker&#39;s products to be less competitive than its principal competitors&#39; offerings.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/6e/80173.jpg?v=35874249" /></p>
<p>Image Source: Zacks Investment Research</p>
<p><strong>Macroeconomic Factors:</strong>&nbsp;Present global economic challenges and uncertainties have made it harder for Bruker to manage operations and predict financial outcomes. Geopolitical conditions are impacting its operational results. In addition, supply-chain risks also persist. All these issues are leading to higher costs and expenditures for the company, impacting its profitability.</p>
<p>In the second quarter, Bruker&#39;s cost of revenues increased 21.6% from the same period in 2023. SG&amp;A expenses surged 24.4%.</p>
<h2>BRKR&#39;s Estimate Trend</h2>
<p>The Zacks Consensus Estimate for Bruker&#39;s 2024 earnings per share remained unchanged at $2.61 for the past 30 days.</p>
<p>The consensus estimate for the company&#39;s 2024 revenues is pegged at $3.41 billion, indicating a 14.9% rise from the year-ago &nbsp;number.</p>
<h2>Key Picks</h2>
<p>Some better-ranked stocks in the broader medical space are&nbsp;<strong>TransMedix Group</strong>&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>),&nbsp;<strong>AxoGen </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axgn#NASDAQ">AXGN</a>) and <strong>Phibro Animal Health </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pahc#NASDAQ">PAHC</a>).</p>
<p>TransMedix Group&#39;s earnings are expected to surge 255.8% in 2024. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 287.5%. Shares of the company have risen 173.5% in the past year compared with the industry&#39;s 22.4% growth. TMDX sports a Zacks Rank #1 (Strong Buy) at present.</p>
<p>AxoGen, carrying a Zacks Rank #2 (Buy) at present, has an earning yield of 94.1% compared with the industry&#39;s 12.3%. Shares of the company have risen 194.6% compared with the industry&#39;s 22.3% growth over the past year.&nbsp;AXGN&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.46%.</p>
<p>Phibro, carrying a Zacks Rank of 2 at present, has an estimated earnings growth rate of 21% for fiscal 2025 compared with the industry&#39;s 12.6%. In the past year, shares of PAHC have risen 72.7% compared with the industry&#39;s 25.2% growth. PAHC delivered a trailing four-quarter average earnings surprise of 4.10%.</p>
<p><a href="https://www.zacks.com/stock/news/2345297/here-s-why-you-should-retain-brkr-stock-in-your-portfolio-now?cid=CS-BENZ-FT-analyst_blog|rank_focused-2345297">To read this article on Zacks.com click here.</a></p>


Macro Economic Events

Economics

PAHC

Here's Why You Should Retain BRKR Stock in Your Portfolio Now

<p>This acquisition strengthens Bruker&#39;s biophysical portfolio for the analysis of molecular interactions and kinetics, offering deeper insights into both inter-molecular and molecule-single cell interactions in drug discovery or basic research.</p>
<p>In FY2025, Bruker Biosensors expects additional revenues greater than&nbsp;$5 million&nbsp;from the DBS acquisition, with no material EPS impact.</p>


Bruker Acquires Germany-Based Dynamic Biosensors GmbH; Financial Details Not Disclosed

<p>In the last three months, 4 analysts have published ratings on Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $72.5, along with a high estimate of $80.00 and a low estimate of $60.00. This current average has decreased by 9.75% from the previous average price target of $80.33. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727701209_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The standing of Bruker among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$78.00</td>
<td>-</td>
</tr>
<tr>
<td>Max Masucci</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$72.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$80.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$60.00</td>
<td>$72.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Bruker. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bruker compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Bruker's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BRKR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Bruker analyst ratings.</strong></a></p>
<h2>All You Need to Know About Bruker</h2>
<p>Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific.</p>
<h3>Unraveling the Financial Story of Bruker</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Bruker showcased positive performance, achieving a revenue growth rate of <strong>17.42%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Bruker's net margin excels beyond industry benchmarks, reaching <strong>0.95%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Bruker's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.47%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Bruker's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.15%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Bruker's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>1.27</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Scoreboard: 4 Ratings For Bruker

<p>Wolfe Research  analyst Doug Schenkel   downgrades Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) from Outperform to Peer Perform.</p>


Downgrades

Wolfe Research Downgrades Bruker to Peer Perform

<p>Wells Fargo  analyst Brandon Couillard   initiates coverage on Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Overweight rating and announces Price Target of $78.</p>


Wells Fargo Initiates Coverage On Bruker with Overweight Rating, Announces Price Target of $78

Asia's First 1.2 GHz NMR System Installed At Korea Basic Science Institute, Enhancing Molecular And Disease Research Capabilities

<p>TD Cowen  analyst Max Masucci   maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Hold and lowers the price target from $74 to $72.</p>


TD Cowen Maintains Hold on Bruker, Lowers Price Target to $72

<p>The minority investment aims to accelerate the growth and further expansion of NovAliX, particularly within Europe and the United States.&nbsp;</p>


Bruker Announced A Minority Investment In NovAliX, A Preclinical Contract Research Organization Specializing In Drug Discovery Services, Financial Details Of The Investment Were Not Disclosed

Bruker Sees FY24 Adj. EPS $2.59-$2.64 vs $2.64 Est., Revenues $3.38B-$3.44B vs $3.4B Est.

<p>Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) reported quarterly earnings of $0.52 per share which met the analyst consensus estimate.  The company reported quarterly sales of $800.700 million which beat the analyst consensus estimate of $796.541 million by 0.52 percent.  This is a 17.42 percent increase over sales of $681.900 million the same period last year.</p>


Bruker Q2 2024 Adj. EPS $0.52, Inline, Sales $800.700M Beat $796.541M Estimate

Bruker Posted Bond In Order To Suspend Injunction That Had Been Impacting Sales Of CosMx Spatial Molecular Imager Products By Its NanoString Business In Germany

Bruker (BRKR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Brandon Couillard from Wells ...

Positive Outlook on Bruker Amid Legal Wins and Competitive Edge in Spatial Molecule Imaging

Waters sends peers higher after Q3 beat, guidance raise

Bruker: Still Challenged, Certainly Margins

Bruker Q3 2024 Earnings Preview

Here's the major earnings before the open tomorrow

Bruker Non-GAAP EPS of $0.60, revenue of $864.4M

Sees FY24 organic revenue growth of 3% to 4%: Contribution from M&A of approximately 9.5%, revenue consensus $3.4B. Published first on TheFly – the...

Bruker Sees FY24 EPS $2.36-$2.41 , consensus $.2.59

Bruker Corporation 2024 Q3 - Results - Earnings Call Presentation

BofA lowered the firm's price target on Bruker (BRKR) to $78 from $79 and keeps a Buy rating on the shares. Bruker's Q3 results came in below estim...

Bruker price target lowered to $78 from $79 at BofA

TD Cowen analyst Daniel Brennan maintained a Hold rating on Bruker (BRKR – Research Report) today and set a price target of $70.00. Daniel Brennan'...

Bruker: Navigating Challenges with a Balanced Hold Rating Amid Sector Headwinds and Recovery Opportunities

ACDC

AGCO

APLS

ARCH

BEAM

BLDP

BLDR

CEIX

CNSL

DHLGY

DNNGY

ENDPQ

EXPD

GLDD

GOGO

HSIC

INGR

KPTI

LGIH

MITT

MLCO

MPLX

NMRK

ONIT

OXSQ

PAYO

PMTS

PTLO

RACE

RVTY

SHIP

SNDL

SQNS

TCNNF

TRGP

USAC

VWDRY

WLKP

Biotech

Press Releases

Biognosys Announces Commercial Availability of NULISA™ Proteomics Assay Services for Biomarker Research

Financing

Biognosys Enters Reselling Agreement for Spectronaut Proteomics Software with Leading Provider of Mass Spectrometry Systems

Bruker Acquires Dynamic Biosensors, a Pioneer of Single-Cell Interaction Cytometry Systems for Drug Discovery

Bruker Introduces Innovative Neuroscience Research Solution with High-Speed OptoVolt Voltage Imaging

Bruker Announces Formation of New Bruker Spatial Biology Division

Biognosys Presents Major Innovations Across the Spectrum of Proteomics Research Applications at the HUPO World Congress

European Unified Patent Court Rules in Favor of Bruker and NanoString, Invalidating Patent Asserted By 10x Genomics against NanoString's CosMx SMI Products

Bruker Announces One-Hundred Dollar, Deep, High-Accuracy Plasma Proteome; Advances Glycoproteomics and Metaproteomics

Bruker Announces Date and Time of Third Quarter 2024 Earnings Release and Webcast

Bruker Reports Third Quarter 2024 Financial Results

Agilent Technologies

AbCellera Biologics

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Bruker

Vendite allo scoperto

Bruker (NASDAQ:BRKR) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO